Berenberg Ups Galderma Price Target as Q3 Results Exceed Expectations

10:07 AM EDT, 10/26/2026 (MT Newswires) -- Berenberg raised its price target for Galderma Group (GALD.SW) to 214 francs from 204 francs after the dermatology company's third-quarter results again outperformed expectations, leading to an upgraded 2026 constant-currency sales growth guidance. "Constant currency (cc) sales growth of 26.0% was over 600bp ahead of company-compiled consensus; every division reported growth ahead of forecasts. Market conditions remained more resilient than the company expected, and management upgraded its top-line growth outlook for FY26 cc sales growth by 3ppt at the midpoint," analysts said in a note published Monday. Analysts also affirmed their confidence in Galderma's "trailblazer status within dermatology" and said they expect further consolidation of its long-term self-care leadership. The research firm also updated its forecasts for 2026 through 2028, including higher sales and EPS estimates for all three years, as it took into account currency movements and the company's latest commentary. The buy recommendation on the Swiss stock was retained.